U.S. markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,857.30
    +3.40 (+0.18%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.01%)
     
  • BTC-USD

    28,855.29
    +4.47 (+0.02%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.

  • The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program.

  • Related: Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation.

  • As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness. Achieve may borrow additional non-convertible term loans of up to $10 million.

  • The outstanding convertible debt may be converted into Achieve's common shares at a conversion price equal to $9.34 per share,

  • Price Action: ACHV shares are up 3.11% at $7.80 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.